RxDoctor Payments Data
★ My doctorsLook up a doctor →

Lewis Kanter

Camarillo, CANPI 1013910827

Payments from drug & device makers

$4,579in general payments, 2019–2025

Across 226 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Boehringer Ingelheim$509
  • AstraZeneca$466
  • Takeda Pharmaceuticals U.S.A., Inc.$317
  • Regeneron Healthcare Solutions, Inc.$267
  • Pfizer$204
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK70$1,172
Boehringer Ingelheim29$509
AstraZeneca29$466
Takeda Pharmaceuticals U.S.A., Inc.14$317
Regeneron Healthcare Solutions, Inc.9$267
Pfizer10$204
Kaleo, Inc.9$181
Sanofi8$174
Novartis8$155
Biocryst US Sales Co., LLC2$151
CSL Behring6$140
Shire North American Group Inc2$132
Optinose US, Inc.7$126
Octapharma USA, Inc.3$124
Circassia Inc.1$95
Teva Pharmaceuticals USA, Inc.4$75
Grifols USA, LLC3$56
Merck2$45
Genentech USA, Inc.2$38
LEO Pharma Inc.1$25
Aimmune Therapeutics, Inc.1$24
Biocryst Pharmaceuticals, Inc.1$23
Amgen1$21
Bio Products Laboratory USA, Inc.2$21
Sanofi Pasteur Inc.1$20
Incyte Corporation1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →